IL33 and glioblastoma: We find that ~50% of surgical samples that cover the molecular and clinical heterogeneity of GBM patients, and their corresponding BTIC cultures, express and secrete IL-33 in vivo, which in turn alters resident microglia, and the recruitment and activation of bone-marrow-derived macrophages (BMDMs), natural killer cells, and T cells.